[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100484949":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":22,"locations":31,"responsibleParty":53,"collaborators":55,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":10,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":10,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"University Hospital, Geneva","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Newly diagnosed patients with T1DM",null,"The investigators will do prospective measures in 10 to 15 children aged 2 to 18 years, at the time of diagnosis, four months after diagnosis and one year after diagnosis.",[13],"Other: Measurement of blood levels of 1,5-anhydroglucitol",{"label":15,"type":10,"description":16,"interventionNames":17},"Patients with T1DM of different duration","As the functional beta-cell mass gradually declines as disease duration increases, the investigators will do measurements in a cohort of children aged ≤ 18 years, with increasing diabetes duration. The investigators plan to analyze groups of 5 patients with a disease duration of 3 (36 - 47 months), 5 (60 - 71 months) and 10 years (120 - 131 months), respectively.",[13],[19],{"type":6,"name":20,"description":20,"armGroupLabels":21,"otherNames":10},"Measurement of blood levels of 1,5-anhydroglucitol",[9,15],[23,28],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Philippe Klee","CONTACT","+41 22 372 45 90","philippe.klee@unige.ch",{"name":29,"role":25,"phone":10,"phoneExt":10,"email":30},"Pierre Maechler","pierre.maechler@unige.ch",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"University Hospital of Geneva","RECRUITING","Geneva","Canton of Geneva","1211","Switzerland","CH",{"type":41,"coordinates":42},"Point",[43,44],6.14569,46.20222,{"lat":44,"lon":43},[47,51],{"name":48,"role":25,"phone":49,"phoneExt":10,"email":50},"Philippe Klee, MD-PhD","+41 79 55 33 476","philippe.klee@hcuge.ch",{"name":48,"role":52,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":52,"investigatorFullName":48,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Principal investigator",[56],{"name":57,"class":6},"University of Geneva, Switzerland","100484949","anhydroglucitol-in-children-with-type-1-diabetes-100484949",false,"NCT05594706","Anhydroglucitol in Children With Type 1 Diabetes","Anhydroglucitol as a Measure of the Functional Beta-cell Mass in Children With Type 1 Diabetes - Pilot Study","Inclusion Criteria:\n\n* Type 1 diabetes with positive autoantibodies against islets, insulin, islet antigen 2 (IA2), glutamic acid decarboxylase (GAD) 65 or zinc transporter (ZnT)8.\n* Treatment with continuous subcutaneous insulin infusion (CSII) with or without automated insulin delivery (AID).\n* Monitoring with a continuous glucose measurement system (CGMS) or flash glucose monitor (FGM).\n* Patient willing to keep the same type of CGMS or FGM during the year of observation\n* Ability to give informed consent as documented by signature\n\nExclusion Criteria:\n\n* Patients treated with multiple daily injections (MDI) or not willing to wear a CGMS of FGM\n* Patients changing the type of CGMS during the course of the study.",true,"ALL","2 Years","18 Years",{"count":70,"type":71},60,"ESTIMATED","OBSERVATIONAL","The investigators will measure blood levels of 1,5-anhydroglucitol in children with type 1 diabetes and correlate them with parameters related to functional beta-cell mass in diabetic patients. The values will be compared to those obtained in healthy volunteers. Children with newly diagnosed diabetes as well as children with longstanding disease will be included. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in type 1 diabetes.",[75],"Diabetes Mellitus, Type 1","2026-05-14",{"date":78,"type":79},"2026-05-18","ACTUAL",{"date":81,"type":79},"2023-01-27",{"date":83,"type":71},"2026-12-31",{"name":5,"class":6},1]